Brief: Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
02/12/2024 14:19
Dec 2 (Reuters) - Sana Biotechnology Inc SANA.O :
* SANA BIOTECHNOLOGY ANNOUNCES FAST TRACK DESIGNATION FOR
SC291 IN
RELAPSED/REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
* SANA BIOTECHNOLOGY INC - EXPECT TO REPORT INITIAL CLINICAL
DATA
IN 2025 IN GLEAM TRIAL FOR SC291 IN B-CELL MEDIATED AUTOIMMUNE
DISEASES
Source text: ID:nGNX1n4qht
Further company coverage: SANA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sana Biotechnology
See all newsSana Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Sana Biotechnology Q2 adjusted loss narrows, beats estimates
Brief: Sana Biotechnology Q2 Adjusted EPS USD -0.13 Vs. IBES Estimate USD -0.15
Sana Biotechnology posts Q1 adjusted loss narrower than expected, extends cash runway
Brief: Sana Biotechnology Q1 Adjusted EPS USD -0.14 Vs. IBES Estimate USD -0.17